Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: Chrysalin (Orthologic).

Kathleen E Rodgers¹

¹University of Southern California, School of Medicine, 1321 North Mission Road, Los Angeles, CA 90033-1020, USA. krodgers@usc.edu

Current Opinion in Molecular Therapeutics

|June 28, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling.

Frontiers in immunology·2026

Same author

Impaired parasympathetic network function confers susceptibility to neurodegeneration and memory impairment in older adults with elevated beat-to-beat blood pressure variability.

Journal of Alzheimer's disease : JAD·2025

Same author

Beat-to-beat blood pressure variability, hippocampal atrophy, and memory impairment in older adults.

GeroScience·2024

Same author

Central autonomic network dysfunction and plasma Alzheimer's disease biomarkers in older adults.

Alzheimer's research & therapy·2024

Same author

Advancements and challenges in amyotrophic lateral sclerosis.

Frontiers in neuroscience·2024

Same author

Short-term blood pressure variability and brain functional network connectivity in older adults.

Neuroimage. Reports·2024

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

Chrysalin, a synthetic peptide, is being studied for wound healing and tissue regeneration. This peptide shows promise in clinical trials for diabetic foot ulcers, cartilage repair, and bone fractures.

Area of Science:

Biochemistry
Regenerative Medicine
Clinical Trials

Background:

OrthoLogic is developing Chrysalin, a novel synthetic peptide.
Chrysalin is a 23-amino acid peptide designed to mimic a segment of human thrombin.

Purpose of the Study:

To evaluate Chrysalin's efficacy in treating diabetic foot ulcers.
To assess Chrysalin's potential for cartilage repair and bone fracture healing.

Main Methods:

Phase II clinical trials for diabetic foot ulcers.
Phase III clinical trials for cartilage repair and bone fractures.

Main Results:

Data on clinical trial outcomes are pending.
Pre-clinical data suggests potential therapeutic benefits.

Related Experiment Videos

Conclusions:

Chrysalin is under investigation for multiple orthopedic and wound healing applications.
Further clinical evaluation is required to establish safety and efficacy.